Pipeline Therapeutics to Participate in Upcoming October 2023 Investor Conferences

04 Oct 2023
www.biospace.com
License out/inPhase 1
SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming investor conferences: Jefferies Biotech CNS/Neuro Summit, October 11-12, 2023, NY, NY 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, October 17-18, 2023 Leerink Virtual Biopharma Private Company Connect, October 25-26, 2023 About Pipeline Therapeutics Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. In April 2023, Pipeline announced that it entered into a global license and development agreement with Janssen Pharmaceutica NV (Janssen) for its lead program, PIPE-307, a highly selective M1 antagonist, in central nervous system disorders. The Company’s lead wholly-owned program, PIPE-791, an LPA1 receptor antagonistLPA1 receptor antagonist, is advancing through Phase 1 testing to support treatment of neurological diseases. For more information, please visit and engage with us on LinkedIn. View source version on businesswire.com: Contacts Company Contact: Peter Slover CFO ir@pipeline-tx.com Investor Contact: Amy Conrad amy@juniper-point.com Source: Pipeline Therapeutics View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.